Filtered By:
Therapy: Hormonal Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 218 results found since Jan 2013.
Testosterone Treatments Aren ’ t Linked to Heart Risks When Patients Are Carefully Monitored, Study Finds
Advertisements for treatments for “low T,” or low testosterone levels in middle-aged and older men, have led to spikes in demand. But the safety and legitimacy of those testosterone therapies hasn’t been clear.
In a new study published in the New England Journal of Medicine and presented at the Endocrine Society’s annual meeting, researchers provide the most conclusive evidence yet that testosterone treatments appear to be safe for the heart and are not associated with an increased risk of certain heart-related events.
In the study, led by researchers at the Cleveland Clinic, more than 5,200 men age...
Source: TIME: Health - June 16, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate heart health Source Type: news
Sexual and Gender Diversity in Pediatric Neurology: Why We Care
Sexual and gender diversity (SGD) – an inclusive term describing people who identify outside of heteronormative binary concepts of gender and sexuality – directly affects us in the pediatric neurology clinic. SGD identity can impact various neurological conditions, including headache, epilepsy, and functional neurological disord ers, all of which have been observed at higher rates in the SGD community.1-4 Gender-affirming hormone therapy can interact with medications commonly used to treat neurological conditions1,5,6 and may increase the risk for idiopathic intracranial hypertension7 and stroke.
Source: Pediatric Neurology - April 19, 2023 Category: Neurology Authors: Alison Christy, Jaclyn Martindale, Jennifer Hranilovich, Casey Orozco-Poore, Finley Kernan-Schloss, Chase T.M. Anderson, Jonathan Strober, Wendy Mitchell, Mackenzie P. Lerario Tags: Editorial Source Type: research
Cancers, Vol. 15, Pages 2316: Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
K. Kelly
Androgen deprivation therapy is the cornerstone of prostate cancer therapy. Recent studies have revealed an association between androgen deprivation therapy and cardiovascular adverse effects such as myocardial infarction and stroke. This review summarizes the available research on the cardiovascular risk of men using androgen deprivation therapy. We also discuss racial disparities surrounding both prostate cancer and cardiovascular disease, emphasizing the importance of biological/molecular and socioeconomic factors in assessing baseline risk in patients beginning androgen ablation. Based on the literature, ...
Source: Cancers - April 15, 2023 Category: Cancer & Oncology Authors: James Fradin Felix J. Kim Grace L. Lu-Yao Eugene Storozynsky William K. Kelly Tags: Review Source Type: research
Transgender health and the impact of aging and menopause
Climacteric. 2023 Apr 3:1-7. doi: 10.1080/13697137.2023.2176217. Online ahead of print.ABSTRACTGender affirming hormone therapy (GAHT) is used by many transgender people to reduce gender incongruence and improve psychological functioning. As GAHT shares many similarities with menopausal hormone therapy, clinicians supporting people through menopause are ideally placed to manage GAHT. This narrative review provides an overview of transgender health and discusses long-term effects of GAHT to consider when managing transgender individuals across the lifespan. Menopause is less relevant for transgender individuals who take GAH...
Source: Climacteric - April 3, 2023 Category: Geriatrics Authors: A S Cheung B J Nolan S Zwickl Source Type: research
Hormones for Gender Dysphoria Associated With Cardiovascular Risk Hormones for Gender Dysphoria Associated With Cardiovascular Risk
Largest study to date examining risks of gender-affirming hormone therapy finds increased risks for some cardiovascular events, including notably stroke and heart attack.Medscape Medical News
Source: Medscape Cardiology Headlines - March 10, 2023 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
Longer oestrogen exposure could slash the risk of having a stroke, study suggests
The findings suggest that extending oestrogen exposure with hormone therapy could reduce the risk of stroke.
Source: Daily Express - Health - February 2, 2023 Category: Consumer Health News Source Type: news
The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies
The re-analysis of Women's Health Initiative and the publication of data emerging from recent clinical trials data have restored the initial decline in the use of menopausal hormone therapy (MHT), due to adverse events, such as stroke and pulmonary embolism [1,2]. Nowadays, an increasing number of women treat their menopausal symptoms with hormonal therapies, which exhibit a better safety profile. However, the association of MHT with cancer development remains a potent drawback, with breast and endometrial cancer being the most frequently reported neoplasms [3,4].
Source: Maturitas - November 4, 2022 Category: Primary Care Authors: Konstantinos Lallas, Panagiotis Anagnostis, Patroklos Theocharis, Eirini Boureka, Athanasios Kyrgidis, Eleftherios Klonos, Georgios Papazisis, Zoe Apalla, Aimilios Lallas, Efstratios Vakirlis Tags: Review article Source Type: research
Menopausal hormone therapy with conjugated equine estrogen is associated with a higher risk of hemorrhagic stroke than therapy with estradiol: a retrospective population-based cohort study
Estrogen therapy is prescribed for women without a uterus. For women with intact uteri, progestogens should be added to protect against endometrial hyperplasia. Different estrogen profiles may cause different side effects and beneficial clinical outcomes [1]. Different forms of estrogen also have different serum E2 concentrations; a previous study demonstrated that 1 mg E2 was equivalent to 0.4 mg CEE [1]. Progestin includes medroxyprogesterone acetate (MPA) and norethindrone acetate (NE). In Taiwan, the most common MHT for patients with an intact uterus are CEE (0.625 mg) or E2 (2 mg) combined with 5 mg MPA or 1 mg NE [2,3].
Source: Maturitas - August 1, 2022 Category: Primary Care Authors: Wei-Chuan Chang, Jen-Hung Wang, Dah-Ching Ding Tags: Original article Source Type: research
Growth hormone therapy for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: A case report
Asian J Surg. 2022 Jul 18:S1015-9584(22)00981-2. doi: 10.1016/j.asjsur.2022.07.035. Online ahead of print.NO ABSTRACTPMID:35864039 | DOI:10.1016/j.asjsur.2022.07.035
Source: Asian Journal of Surgery - July 21, 2022 Category: Surgery Authors: Qiong Tang Xiao-Min Ye Yi-Can Yang Xiang-Lan Wen Source Type: research
Diagnosis, Treatment, and Prevention of Stroke in Transgender Adults
AbstractPurpose of ReviewTo identify the current state of science on stroke in transgender adults and highlight gaps in need of further research. We will review current research on cerebrovascular risk and disease, hormone therapy, and stroke in transgender individuals. Finally, we will provide a framework for healthcare providers to prevent and reduce disparities through inclusive care practices.Recent FindingsTransgender people experience unique stroke risk factors, secondary to both psychosocial stress and health-related behaviors. These include higher rates of HIV, tobacco use, stimulant use, and hepatitis C. The use o...
Source: Current Treatment Options in Neurology - July 11, 2022 Category: Neurology Source Type: research
Sex and Gender Considerations in Episodic Migraine
AbstractPurpose of ReviewWe seek to update readers on recent advances in our understanding of sex and gender in episodic migraine with a two part series. In part 1, we examine migraine epidemiology in the context of sex and gender, differences in symptomatology, and the influence of sex hormones on migraine pathophysiology (including CGRP). In part 2, we focus on practical clinical considerations for sex and gender in episodic migraine by addressing menstrual migraine and the controversial topic of hormone-containing therapies. We make note of data applicable to gender minority populations, when available, and summarize kn...
Source: Current Pain and Headache Reports - June 9, 2022 Category: Neurology Source Type: research
Menopausal hormone therapy and risk of cardiovascular events in women with prediabetes or type 2 diabetes: A pooled analysis of 2917 postmenopausal women
CONCLUSIONS: MHT is associated with statistically reduced CVD risk among white but not black women with PreDM or DM. Race is an effect modifier in the association between MHT use and CVD.PMID:35114556 | DOI:10.1016/j.atherosclerosis.2022.01.016
Source: Atherosclerosis - February 3, 2022 Category: Cardiology Authors: Yilin Yoshida Zhipeng Chen Robin L Baudier Marie Krousel-Wood Amanda H Anderson Vivian A Fonseca Franck Mauvais-Jarvis Source Type: research
The impact of micronized progesterone on cardiovascular events - a systematic review
In conclusion, while available data suggest that MP as a component in combined MHT may have a neutral effect on the vascular system, more RCTs investigating the impact of MP alone or in combined MHT on vascular primary endpoints are needed.PMID:35112635 | DOI:10.1080/13697137.2021.2022644
Source: Climacteric - February 3, 2022 Category: Geriatrics Authors: L M Kaemmle A Stadler H Janka M von Wolff P Stute Source Type: research
